Butamben
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Butamben: Local anesthetic (sodium channel blocker) → Bronchitis
One-Sentence Summary
Butamben is a topical ester-type local anesthetic. The TxGNN model predicts it may be effective for bronchitis, but no clinical trials and no publications were found to support this prediction, so it remains a computational hypothesis only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Bronchitis |
| TxGNN Prediction Score | 0.9979 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Butamben is generally understood as a local anesthetic that blocks voltage-gated sodium channels in nerve membranes.
A theoretical link to bronchitis would be dampening of airway sensory nerve activity, which drives the cough reflex. This is speculative: no data were compiled showing that butamben has been tested for this purpose, and the route of administration needed for airway delivery has not been assessed. The high score reflects a computational prediction only and should not be read as evidence of benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02028867 | CETACAINE LIQUID | Not recorded | Not recorded |
Safety Considerations
- Safety signals to be aware of (not label text): Butamben is linked in the underlying prediction data to epilepsy, sudden cardiac arrest, heart conduction disease and respiratory failure as conditions of concern. These are not taken from the product label and should be checked against the package insert.
- No drug interaction records were found.
Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. There are no clinical trials or publications for bronchitis, the mechanism of action data are missing, and the evidence level is L5.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data for butamben
- Preclinical or clinical evidence that directly studies butamben in bronchitis
- An assessment of whether a suitable route of administration exists for airway use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.